The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Merck to stop phase III LYNK-003 trial evaluating Lynparza with or without bevacizumab in metastatic colorectal cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Merck plans to stop the phase III LYNK-003 trial investigating Lynparza with or without bevacizumab for the treatment of patients with unresectable or metastatic colorectal cancer who have not progressed following first-line induction, citing futility. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Intismeran autogene + Keytruda improves RFS and DMFS in melanoma patients, phase III INTerpath-001 trial finds

Intismeran autogene (intismeran; V940 or mRNA-4157), a novel investigational mRNA-based individualized neoantigen therapy, plus Keytruda (pembrolizumab) improved recurrence-free survival and distant metastasis-free survival as an adjuvant treatment for patients with completely resected stage 2B-4 melanoma, according to results of the phase III INTerpath-001 trial. 
Clinical Roundup

ChristianaCare study identifies potential drug combination for making CRC more responsive to retinoids

A study from researchers at ChristianaCare’s Helen F. Graham Cancer Center & Research Institute identifies a potential way to make colorectal cancer more responsive to retinoids, compounds related to vitamin A that can help regulate how cells grow and mature. The article “Inhibition of WNT signaling sensitizes CRC cells to anti-tumor effects of retinoids: Basis for new drug combinations in oncology,” 
Podcast

A new diagnostic lens—and a lasting scientific legacy

In this week's episode of The Cancer Letter Podcast, editor and publisher Paul Goldberg, and associate editor Jacquelyn Cobb revisit two of last week’s most-read stories: the growing recognition that early-onset colorectal cancer requires a new diagnostic mindset, and the life and legacy of Maura Gillison, the scientist whose discovery that most head and neck cancers are driven by HPV transformed the field. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account